Mónica Povedano is an expert in neuromuscular disease and obtained her medical degree from the University of Barcelona. She is a specialist in Neurophysiology and currently coordinates the Motor Neuron Functional Unit of the Service of Neurology at the Bellvitge University Hospital, Institute of Biomedical Research of Bellvitge (IDIBELL). The Motor Neuron Functional Unit treats patients with ALS, SMA and other motor neuron diseases and is a referral centre for the local community and beyond. Her research interests are many, and include the study of subgroups of ALS, biomarker analysis, epidemiology, genetics but also to find treatments to improve swallowing and nutrition in ALS patients. Finally, she is also interested in interventions to prevent cognitive decline in patients with ALS. In 2017 she received an award for Professional Excellence from the Barcelona Medical College.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.